Familiar Hypercholesterolemia (FH)
In LATAM, FH is largely underdiagnosed and undertreated as a result of the lack of general awareness of the disease. Considering a prevalence of 1/300-500 for the heterozygous and 1/300,000-1,000,000 for the homozygous, it is estimated that there are at least 1,250,000 to 2.5 million people with FH in the region (28). Despite high LDL-C and even after an atherosclerotic event, a large proportion of individuals with FH remain unidentified and untreated. FH is a clear example of high-risk patients, with very high levels of LDL-C in which it is necessary to have an accurate and timely diagnosis and an aggressive treatment approach (29-30).
Treatment of LDL-C
The most important groups of hypolipidemic drugs available for the treatment of LDL-C supported by scientific evidence are statins, ezetimibe, and PCSK9 inhibitors (PCSK9i).